- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Ritedose to Manufacture Tenpoint Therapeutics' Presbyopia Eye Drop
Partnership signals commercial readiness and manufacturing strength for groundbreaking ophthalmic treatment
Apr. 8, 2026 at 10:49pm
Got story updates? Submit your updates here. ›
Cutting-edge ophthalmic technology powers a new treatment for the aging eye.Columbia TodayThe Ritedose Corporation, the largest contract development manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production, is partnering with Tenpoint Therapeutics to manufacture YUVEZZI™, the first and only dual-agent eye drop FDA-approved for the treatment of presbyopia.
Why it matters
The selection of Ritedose as a CDMO reflects Tenpoint's commitment to commercial readiness and supply security. In the ophthalmic space, where validated sterile manufacturing and rigorous quality oversight are critical, partnering with an experienced manufacturer like Ritedose helps de-risk the production pathway and demonstrates Tenpoint's discipline in choosing best-in-class partners.
The details
Ritedose has over 25 years of experience in sterile ophthalmic and respiratory manufacturing, making it the ideal partner to deliver safe and effective doses of YUVEZZI to patients. The partnership will allow Tenpoint to bring this groundbreaking treatment to the nearly 128 million people in the US and 2 billion globally who suffer from presbyopia.
- Ritedose and Tenpoint Therapeutics announced the partnership on April 8, 2026.
The players
The Ritedose Corporation
The largest contract development manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets.
Tenpoint Therapeutics, Ltd.
A commercial-stage ophthalmic pharmaceuticals company focused on the commercialization of YUVEZZI™, the first and only dual-agent eye drop for the treatment of presbyopia.
Jody Chastain
President and CEO of Ritedose.
What they’re saying
“Our leading aseptic manufacturing capabilities make Ritedose the ideal partner to deliver safe and effective doses of YUVEZZI to patients.”
— Jody Chastain, President and CEO of Ritedose
“Ritedose is proud to work alongside Tenpoint Therapeutics on the manufacturing of national launch quantities of YUVEZZI so this treatment can be available to all presbyopia patients who need it.”
— Jody Chastain, President and CEO of Ritedose
What’s next
Ritedose and Tenpoint Therapeutics will work together to manufacture and distribute YUVEZZI, the first and only dual-agent eye drop for the treatment of presbyopia, to patients across the United States.
The takeaway
This partnership between Ritedose and Tenpoint Therapeutics demonstrates the importance of reliable, high-quality manufacturing in the ophthalmic pharmaceutical industry. By aligning with an experienced CDMO like Ritedose, Tenpoint has positioned itself to successfully bring this groundbreaking treatment for presbyopia to the millions of people who need it.
